Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms232113278
Abstract: Siponimod (Mayzent®), a sphingosine 1-phosphate receptor (S1PR) modulator which prevents lymphocyte egress from lymphoid tissues, is approved for the treatment of relapsing-remitting and active secondary progressive multiple sclerosis. It can cross the blood–brain barrier (BBB)… read more here.
Keywords: modulates reaction; microglial cells; reaction microglial; siponimod modulates ... See more keywords